Swiss National Bank Has $1.81 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Swiss National Bank trimmed its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 0.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,300 shares of the specialty pharmaceutical company’s stock after selling 600 shares during the period. Swiss National Bank owned about 0.20% of Collegium Pharmaceutical worth $1,814,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. AlphaQuest LLC lifted its stake in shares of Collegium Pharmaceutical by 3.0% in the fourth quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock valued at $366,000 after buying an additional 374 shares during the period. Kendall Capital Management lifted its position in shares of Collegium Pharmaceutical by 31.6% in the 4th quarter. Kendall Capital Management now owns 17,760 shares of the specialty pharmaceutical company’s stock worth $509,000 after acquiring an additional 4,260 shares during the period. Amundi grew its holdings in shares of Collegium Pharmaceutical by 188.3% during the 4th quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company’s stock worth $446,000 after purchasing an additional 10,168 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $2,432,000. Finally, Aigen Investment Management LP acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at $230,000.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now directly owns 177,195 shares in the company, valued at approximately $5,315,850. This represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,193 shares of company stock valued at $3,243,594 in the last three months. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Stock Up 0.5 %

Shares of NASDAQ:COLL opened at $29.71 on Friday. The company’s fifty day moving average is $30.36 and its 200-day moving average is $32.45. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The company has a market capitalization of $935.45 million, a PE ratio of 12.81 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

COLL has been the topic of a number of recent research reports. Piper Sandler decreased their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.